NCT00047190View on ClinicalTrials.gov

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

April 30, 2007

Conditions
Essential ThrombocythemiaPolycythemia VeraPrimary Myelofibrosis
Interventions
DRUG

tipifarnib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00047190 - Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia | Biotech Hunter | Biotech Hunter